Mecolvix

Mesalazine, the active ingredient in Mecolvix, is an aminosalicylate presented as a rectal formulation for local colonic delivery. It is indicated for induction of response and maintenance of remission in mild to moderate ulcerative colitis and other inflammatory bowel disease in adult patients requiring targeted anti‑inflammatory therapy.

GNH USA supplies Mecolvix as a licensed, GDP‑compliant international pharmaceutical product to hospitals, pharmacies and clinics worldwide, meeting stringent quality standards and supporting global therapeutic needs for inflammatory bowel disease management, and ensuring consistent supply across regions.

Mecolvix (mesalazine) is an aminosalicylate used to manage inflammatory bowel disease by reducing colonic inflammation.

- Ulcerative colitis: induces remission and reduces disease activity in mild to moderate cases. - Maintenance of remission in ulcerative colitis: helps sustain symptom‑free periods. - Proctitis (distal ulcerative colitis): provides localized anti‑inflammatory effect in the rectum.

Mecolvix may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Rectal irritation or burning sensation. - Abdominal pain or cramping. - Nausea or mild vomiting. - Headache. - Flatulence or bloating. - Diarrhea.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, rash, swelling). - Bloody stools or severe rectal bleeding. - Acute severe colitis flare. - Significant elevation of liver enzymes. - Renal impairment or failure. - Unexplained fever or systemic infection.

Before initiating Mecolvix, clinicians should evaluate patient suitability and monitor for potential complications. - Assess disease severity: ensure appropriate use in mild to moderate ulcerative colitis. - Monitor renal function: periodic serum creatinine and electrolytes. - Monitor hepatic function: check liver enzymes regularly. - Avoid in patients with known hypersensitivity to mesalazine or other salicylates. - Use with caution in severe ulcerative colitis or when systemic steroids are required. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mecolvix can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Warfarin or other anticoagulants: increased risk of bleeding. - Azathioprine: heightened risk of bone‑marrow suppression. - Methotrexate: potential for enhanced toxicity. - Live vaccines: may reduce vaccine efficacy or increase infection risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal function. - Diuretics: increased risk of renal electrolyte disturbances. - ACE inhibitors or ARBs: monitor renal parameters. - Oral contraceptives: possible reduction in contraceptive effectiveness.